澳大利亚CSL Limited 
总部位于澳大利亚墨尔本市的CSL Limited公司是一家全球化的专业生物制药公司，致力于研发、生产和销售以蛋白质为基础的药物，以治疗和预防严重的人类疾病。CSL集团在研发和生产疫苗和血浆蛋白生物治疗制剂方面拥有90多年的技术经验，为医学与人类健康做出了杰出的贡献，这是公司的一笔宝贵财富。我们将坚定不移地增加以蛋白质为基础的生物药品的研发投入，以满足那些尚未得到满足的医疗需求，并将其作为我们继续成长的根基。

CSL集团包括CSL Bioplasma、以及CSL Behring并购的ZLB Plasma公司。CSL的主要生产基地位于澳大利亚、德国、瑞士与美国境内，它在27个国家共雇用了8600多名员工。

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.

With major facilities in Australia, Germany, Switzerland and the US, CSL has over 10,000 employees working in 27 countries.

Our Areas of Expertise

Plasma Products
Human plasma is used to produce a wide range of life-saving medicines.

Our various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.

The key businesses involved with plasma products include:

CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma

CSL Bioplasma is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We also manufacture and market in vitro diagnostic products through Immunohaematology

Vaccines & Pharmaceuticals
We manufacture and provide influenza vaccine globally.

In Australia and New Zealand, CSL Biotherapies also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.

Research & Development
Our activities at CSL are focused on new product development, life-cycle management and safety of our extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from plasma, traditional biological sources or using recombinant biotechnology. More information is available in the Research & Development section.